Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$297.90−7.33 (-2.40%)
Close on Nov 16, 2026Market cap $8.82BP/E 37.3Yield –
Krystal Biotech total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for Krystal Biotech
Krystal Biotech has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?